95 percent effective Pfizer vaccine awaits US regulatory approval
The eagerness for the corona vaccine is getting more and more with each passing day. Pfizer Inc., meanwhile, said its Corana vaccine was found to be 95 percent effective in its final analysis of Phase III trials. With this, the way has been cleared for the company to apply to the US regulators for final approval in the next few days.
The American pharmaceutical company and its partner BioNtech have said that their vaccine has protected people of all ages and classes from corona and has not yet encountered any serious safety issues. About 44 thousand people have been vaccinated in the trial. Shares of Pfizer jumped 2.7% in premarket trading following the announcement by the pharmaceutical company, while BioNtech shares also gained 7.3 percent.
In the last few days, several news reports have emerged about the corona virus. Moderna Inc has also claimed an effective vaccine of 94.5%, while Russian Sputnik V has also declared its vaccine to be 92% effective. Trial figures will also be revealed by AstraZeneca and Oxford University in the coming days.
According to Pfizer-BioNtech data, 170 people involved in the trial were infected with Covid-19. A total of 8 people fell ill after the vaccine, while 162 people had some complaints after placebo. The vaccine also prevented the disease from becoming serious, with 10 serious cases reported from the Placebo group, according to the analysis. The company has said that the vaccine is more than 94 percent effective even in people above 65 years of age. Most people who were vaccinated tolerated it comfortably. 3.7% of people showed more fatigue after the second dose.
Pfizer-BioNotech has proved to be 90 percent effective, Sputnik five 92 percent and Moderna 94.5 percent effective in the third stage interim results. Tests of these potential vaccines have raised hopes that the corona virus vaccine may soon be found. None of these three are protein-based, but the American company Moderna is probably best suited for Indian conditions, as it does not require much lower temperatures than other potential vaccines. Experts say that the Pfizer-BioNotech vaccine would be unsuitable for India, as it requires a temperature of minus 70 degrees Celsius for its storage.
